A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

The city of Boston is aiming to close the gaps in life expectancy that have long impacted the Black communities. At a Feb. 27 press conference at the Yawkey Club of Roxbury, Mayor ...

Canada’s S&P/TSX Composite Index declined as global markets shifted towards balancing risks, with investors retreating from stocks amid escalating geopolitical tensions in the Middle East. The ...

He has now won the "Services to the Mo Award" at the national Movember charity awards night in London on March 5. Mr Thompson has raised around £130,000 since starting Geordie Jim's Boys and has been ...

Zymeworks Inc., a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported financial results ...

LONDON, March 12, 2026 /PRNewswire/ -- New polling of UK men 1 for The Urology Foundation, reveals that while around 80% of UK men have a nickname for their penis, only 1 in 10 have heard of penile ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2, which regulates cell differentiation, identity, and plasticity, becomes ...

The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

These two stocks could be poised for a bounce back. The post Should you buy low on these ASX healthcare stocks? appeared first on The Motley Fool Australia.

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.